Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
lower decrease » larger decrease (Expand Search), linear decrease (Expand Search), teer decrease (Expand Search)
we decrease » _ decrease (Expand Search), a decrease (Expand Search), nn decrease (Expand Search)
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
lower decrease » larger decrease (Expand Search), linear decrease (Expand Search), teer decrease (Expand Search)
we decrease » _ decrease (Expand Search), a decrease (Expand Search), nn decrease (Expand Search)
-
2041
Random Forest structure with cross-validation.
Published 2025“…The transition and desert zones decreased by 49.7% and 37.9%, respectively. The ERI decreased and was strongly correlated with the OLS. …”
-
2042
Land use change from 1990 to 2020.
Published 2025“…The transition and desert zones decreased by 49.7% and 37.9%, respectively. The ERI decreased and was strongly correlated with the OLS. …”
-
2043
Geographic data.
Published 2025“…The transition and desert zones decreased by 49.7% and 37.9%, respectively. The ERI decreased and was strongly correlated with the OLS. …”
-
2044
Classification accuracy.
Published 2025“…The transition and desert zones decreased by 49.7% and 37.9%, respectively. The ERI decreased and was strongly correlated with the OLS. …”
-
2045
Data Sheet 1_Dual variants of uncertain significance in a case of hyper-IgM syndrome: implications for diagnosis and management.pdf
Published 2025“…</p>Objective<p>This study aims to elucidate the clinical implications of concurrent AICDA and IKBKB homozygous variants in a pediatric patient diagnosed with hyper-IgM syndrome.</p>Methods<p>We present immunological and genetic analysis of a Tunisian patient with two homozygous variants of uncertain significance (VUSs) in the IKBKB and AICDA genes, suspected of causing hyper-IgM and immune deficiency. …”
-
2046
Data Sheet 1_Case report: Significant lesion reduction and neural structural changes following ibogaine treatments for multiple sclerosis.docx
Published 2025“…Ibogaine, a psychoactive alkaloid, has been proposed as a potential neuroregenerative agent due to its multifaceted pharmacological profile. We present two case studies of MS patients who underwent a novel ibogaine treatment, highlighting significant neuroimaging changes and clinical improvements. …”
-
2047
Data Sheet 2_Case report: Significant lesion reduction and neural structural changes following ibogaine treatments for multiple sclerosis.docx
Published 2025“…Ibogaine, a psychoactive alkaloid, has been proposed as a potential neuroregenerative agent due to its multifaceted pharmacological profile. We present two case studies of MS patients who underwent a novel ibogaine treatment, highlighting significant neuroimaging changes and clinical improvements. …”
-
2048
Data Sheet 3_Case report: Significant lesion reduction and neural structural changes following ibogaine treatments for multiple sclerosis.docx
Published 2025“…Ibogaine, a psychoactive alkaloid, has been proposed as a potential neuroregenerative agent due to its multifaceted pharmacological profile. We present two case studies of MS patients who underwent a novel ibogaine treatment, highlighting significant neuroimaging changes and clinical improvements. …”
-
2049
MRI grading systems’ diagnostic accuracy for MD.
Published 2024“…<div><p>Background</p><p>The diagnosis of Meniere’s Disease (MD) presents significant challenges due to its complex symptomatology and the absence of definitive biomarkers. …”
-
2050
MRI-based cochlear hydrops grading and PLE in MD.
Published 2024“…<div><p>Background</p><p>The diagnosis of Meniere’s Disease (MD) presents significant challenges due to its complex symptomatology and the absence of definitive biomarkers. …”
-
2051
Cochlear hydrops classification in MRI systems.
Published 2024“…<div><p>Background</p><p>The diagnosis of Meniere’s Disease (MD) presents significant challenges due to its complex symptomatology and the absence of definitive biomarkers. …”
-
2052
-
2053
-
2054
-
2055
-
2056
-
2057
-
2058
-
2059
-
2060